Neuroprotective and Neurorestorative Effects of Holothuria scabra Extract in the MPTP/MPP+-Induced Mouse and Cellular Models of Parkinson's Disease

Kunwadee Noonong, Prasert Sobhon, Morakot Sroyraya and Kulathida Chaithirayanon*

Department of Anatomy, Faculty of Science, Mahidol University, Bangkok, Thailand

Extracts from Holothuria scabra (HS) have been shown to possess anti-inflammation, anti-oxidant and anti-cancer activities. More recently, it was shown to have neuroprotective potential in Caenorhabditis elegans PD model. Here, we assessed whether HS has neuroprotective and neurorestorative effects on dopaminergic neurons in both mouse and cellular models of PD. We found that both pre-treatment and post-treatment with HS improved motor deficits in PD mouse model induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as determined by grid walk test. This was likely mediated by HS protective and restorative effects on maintaining the numbers of dopaminergic neurons and fibers in both substantia nigra pars compacta (SNpc) and striatum. In a cellular model of PD, HS significantly attenuated 1-methyl-4-phenylpyridinium (MPP+) -induced apoptosis of DAergic-like neurons differentiated from SH-SY5Y cells by enhancing the expression of Bcl-2, suppressing the expression of cleaved Caspase 3 and preventing depolarization of mitochondrial membrane. In addition, HS could stimulate the expression of tyrosine hydroxylase (TH) and suppressed the formation of α-synuclein protein. Taken together, our in vivo and in vitro findings suggested that HS is an attractive candidate for the neuroprotection rather than neurorestoration in PD.

Keywords: Holothuria scabra, MPP+, MPTP, tyrosine hydroxylase, α-synuclein, striatal dopamine

INTRODUCTION

Parkinson's disease (PD) is an age-related neuro-degenerative disorder of the central nervous system that affects more than 10 million people worldwide (Faisal Nouroz et al., 2014). PD is characterized by the presence of intracytoplasmic inclusion Lewy bodies (LB) in nigral dopaminergic neurons, followed by cell death (Silvia Mandel et al., 2009). Although, PD has been discovered many decades ago, the cause of PD is still unclear, and there is no complete cure yet for Parkinson's disease. Levodopa (L-dopa), dopamine precursor, provides only symptomatic relief but fails to restore neuronal degeneration (Faisal Nouroz et al., 2014). Besides, there
is no proven therapy that could prevent neuronal death, i.e., neuroprotection, or restore sick neurons to a normal state, i.e., neurorestoration (Dawson and Dawson, 2002). Interestingly, several recent studies indicate that natural products have potentials as alternative treatments that can confer both neuroprotection and neurorestoration. Phytochemicals from medicinal plants such as triterpene, polyphenol, flavonoid, alkaloid, and glycosides have been reported to have neuroprotective effects against stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease (Sun et al., 2015; Solayman et al., 2017), while resveratrol, curcumin, and ginsenoside were demonstrated to possess an anti-PD effect (Pangestuti and Arifin, 2017). Additionally, many marine organisms also contain biologically active components with similar therapeutic properties. These natural products could be developed into nutraceuticals for neuroprotection and neurorestoration (Bordbar et al., 2011; Pangestuti and Kim, 2011). Sea cucumbers have been reported to possess these potentials, and they have been used in traditional Chinese medicine as tonics and delicacies for a long time. Among these marine organisms is the white sea cucumber, Holothuria scabra (HS), which is an echinoderm belonging to phylum Echinodermata, class Holothuroidea. They are abundant and widely distributed in Africa, Red Sea, South China Sea, South-Pacific, South East Asia, and the Indian Ocean. HS is rich in triterpene glycosides, such as scabriside A, scabriside B, scabriside D, holothurin A3, holothurin A4, fuscocineroside and 24-dehydrocineroside A, phenols, and flavonoids (Honey-Escandón et al., 2015; Pangestuti and Arifin, 2017; Khotimchenko, 2018). In addition, phenolic compounds including friedelin, 3-hydroxybenzaldehyde, and 4-hydroxybenzaldehyde isolated from the whole body of HS showed a high antioxidant activity (Nobsathian et al., 2017). In this context, 4-hydroxybenzaldehyde displayed a significant inhibition of superoxide anion generation and elastase release by human neutrophils (Kuo et al., 2017). Moreover, members of our group have recently reported that HS extracts exhibited anti-Parkinson potential in Caenorhabditis elegans model (Chalorak et al., 2018). However, the effects and mechanisms of HS chemicals on neuroprotection and/or neurorestoration against PD in a mammalian model remains to be demonstrated and elucidated. Therefore, in this study, we aimed to evaluate the effects of HS in the prevention and restoration of PD in MPTP/MPP+-induced mouse and cellular models of Parkinson's disease.

**MATERIALS AND METHODS**

**Chemicals and Reagents**

Culture medium DMEM/F12 was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Fetal bovine serum, penicillin–streptomycin, and phosphate buffer solution were purchased from Invitrogen corporation (Massachusetts, United States). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), retinoic acid (RA), 12-O-tetradecanoylphorbol-13-acetate (TPA), and PMSF protease inhibitor were purchased from Sigma-Aldrich Corporation (St. Louis, MO, United States). Hoechst 33258 was purchased from Abcam (Cambridge, United Kingdom). RIPA buffer, anti-Bcl-2 (15071S), anti-Bax (2774S), and anti-β-actin (4697S) were purchased from Cell Signal Technology (Massachusetts, United States). Anti-cleaved caspase 3 (ab184787), anti-tyrosine hydroxylase (ab75875), anti-α-synuclein (ab3309), and JC-1 assay kit (ab113850) were purchased from Abcam (Cambridge, United Kingdom). Secondary antibody HRP-conjugated anti-rabbit IgG and anti-mouse IgG were purchased from SouthernBiotech (Birmingham, United States). All other chemicals used were of analytical grade.

**Animals**

Wild-type C57BL/6 male mice, 7–8 weeks old (young adult) weighing 20–25 g, were used in this experiment. The animals were randomly housed (n = 5 per cage) for 7 days to acclimatize under a normal 12/12 h light/dark. They were housed in an ambient temperature of 23 ± 1°C with relative humidity of 60 ± 10%. Food and water were provided ad libitum. Fully mature Holothuria scabra (HS) weighing between 350 and 500 g were collected from the Andaman sea and maintained at the Coastal Fisheries Research and Development Center, Prachuapkirikhun, Thailand. They were kept in concrete tanks containing filtered sea water with continuous aeration and fed with algal-based feed until used for the experiments. All protocols of animal handling and experiments in this study were approved by Animal Care and Use Committee, Faculty of Science, Mahidol University.

**Preparation of HS Extract**

HS were anesthetized on ice, and their body walls were dissected out, cut into small pieces, immersed in liquid nitrogen, pulverized, macerated in 95% ethanol solution for 7 days, then filtered twice. The ethanol phase was evaporated under vacuum, then the powder was kept at −20°C until use. The compounds in HS were characterized by using nuclear magnetic resonance spectroscopy as previously described (Nobsathian et al., 2017).

**HS Administration**

To investigate whether HS possesses neuroprotective and neurorestorative potentials, we examined the effects of pretreatment and post-treatment with HS in MPTP-treated C57BL/6 mouse model of PD. Mice were randomly assigned to eight groups (n = 20 per group) consisting of two control and six experimental groups. The mice groups III to VIII were managed to subsequent behavioral tests after completed with MPTP treatment at day 0 and day 3 (Figure 1). HS extract was dissolved in normal saline solution (NSS, 0.9% NaCl).

> Figure 1. HS extract was dissolved in normal saline solution (NSS, 0.9% NaCl).

- **Group I (NSS control group): mice were intraperitoneally injected with normal saline solution for 7 days.**
- **Group II (HS control group): mice were orally administered with HS 10 mg/kg daily for 7 days.**
- **Group III (MPTP group): mice received intraperitoneal injection of MPTP alone at a dose of 25 mg/kg/day for 5 consecutive days.**
- **Group IV (PreIP-HS/MPTP group): mice were intraperitoneally treated with HS (10 mg/kg/day) for 7 days.**
Noonong et al. Neuroprotective and Neurorestorative Effects of *Holothuria scabra* Extract

FIGURE 1 | Timeline of the experimental procedure. Mice were randomly assigned to eight groups (n = 20 per group) consisting of two control [normal saline solution (NSS) control group and *Holothuria scabra* (HS) control group] and six study groups. The mice groups III to VIII were managed to subsequent behavioral tests after completed with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment at day 0 and day 3. HS extract was dissolved in NSS (0.9% NaCl). Mice were euthanized by cervical dislocation.

consecutive days and then MPTP (25 mg/kg/day) for 5 consecutive days.

Group V (PreG-HS/MPTP group): mice were orally administered with HS (200 mg/kg/day) for 7 consecutive days and intraperitoneal injection of MPTP (25 mg/kg/day) for 5 consecutive days.

Group VI (L-dopa group): mice were intraperitoneally injected with MPTP (25 mg/kg/day) for 5 consecutive days and followed by L-dopa (10 mg/kg/day) for 3 consecutive days.

Group VII (PostIP-HS/MPTP group): mice were intraperitoneally injected with MPTP (25 mg/kg/day) for 5 consecutive days. After that, mice were intraperitoneally administered with HS (10 mg/kg/day) for 3 consecutive days.

Group VIII (PostG-HS/MPTP group): mice received intraperitoneal injection of MPTP (25 mg/kg/day) for 5 consecutive days and followed by oral administration of HS (200 mg/kg/day) for 3 consecutive days.

All mice received training trials with an intertrial interval of 4–5 min for 4 days before experiment.

**Grid Walk Test**

The grid walk test was used to determine motor impairments of limb functioning and placement deficits during locomotion. Mice were placed on a grid (40 × 60 × 100 cm; L × W × H with 2.5 × 2.5 cm grid spaces). The number of paw slips through the grid were recorded.

**Immunohistochemistry**

Mice were euthanized by cervical dislocation. To obtain anterior and posterior parts of the brain, mouse brains were carefully removed and cut in coronal plane between bregma 0 and −2.12 mm. Right and left hemispheres were then separated along the sagittal plane. Then, the brains were immediately fixed in Bouin’s solution for 24 h and later embedded in paraffin blocks. Serial sections of mouse brains (5 µm) were deparaffinized and rehydrated. Endogenous peroxidase activity in the tissue was reduced by treatment with 3% H2O2 in 100% methanol. Then, the sections were incubated for 2 h in blocking reagent (4% normal goat serum in 0.1 M PBST pH 7.4). The sections were incubated for 2 h with polyclonal antibody against tyrosine hydroxylase (1:1,000). Subsequently, the sections were washed and then incubated with secondary antibody, HRP-conjugated goat anti-rabbit IgG (1:4,000) for 1 h. Peroxidase activity was visualized by reacting with DAB in 0.05 M tris-buffered saline (pH 7.6). The stained tissues were observed and photographed under Nikon E600 microscope equipped with Nikon digital DXM1200 camera, using an ACT-1 software package. Tyrosine hydroxylase (TH) intensity in the SNpc and striatum was measured in TH-positive cells and fibers, and quantified with image J version 1.51k.

**Cells and Cell Culture**

SH-SY5Y cells were obtained from the American Type Culture Collection (United States) and cultured in DMEM/F12 with 10%
fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 µg/ml). Culture medium was changed every 3–4 days. Cells were maintained in a humidified 5% CO₂ atmosphere at 37°C. To initiate neurodifferentiation, SH-SY5Y cells were sequentially treated with 10 µM of retinoic acid (RA) for 3 days followed with 80 nM of 12-O-tetradecanoylphorbol-13-acetate (TPA) for 3 days. Finally, SH-SY5Y cells were differentiated and developed into dopaminergic (DAergic)-like neurons as shown by dopamine (DA) synthesis and dopamine transporter (DAT) expression (Xie et al., 2010).

Cytotoxicity Assay for Holothuria scabra
DAergic-like neurons were plated into 96-well plates at a density of 5,000 cells/well. After 24 h, cells were treated with HS for 24 and 48 h in concentrations ranging from 0.5, 1, 5, 10, and 50 µg/ml. The control group was treated with 0.1% DMSO. After treatment, cell viability was determined by using the MTT assay. Briefly, 100 µl of MTT at a concentration 0.5 mg/ml was added into each well of a 96-well plate. After 3 h of incubation at 37°C, MTT solution was removed, and formazan crystals were dissolved with 100 µl of DMSO. The purple color being formed was measured spectrophotometrically at 570 nm (reference OD 690). Cell viability was calculated using Prism 6 software. The suitable concentration of HS was selected for a later experiment.

Cell Treatments With Holothuria scabra and 1-Methyl-4-Phenylpyridinium
HS extract was dissolved in DMEM/F12 with 2% FBS. The HS concentrations at 0.5, 1, and 5 µg/ml were added to DAergic-like neurons. Then, cells were maintained in a humidified 5% CO₂ atmosphere at 37°C for 24 and 48 h. After washing with 1 × PBS, 500 µM of MPP⁺ was added into the culture plate and incubated for 24 h in a humidified 5% CO₂ atmosphere at 37°C. Ultimately, cell viability was determined by using the MTT assay.

Hoechst 33258 Staining
Hoechst 33258 staining was used to illustrate DNA fragmentation condensation that occurred in apoptotic cells. DAergic-like neurons at 1.5 × 10⁵ was cultured on a cover slip and then fixed with 4% formaldehyde for 10 min. Subsequently, fixative solution was removed, and drops of Hoechst stain, at a concentration was added into the culture plate and incubated at room temperature for 15 min. After that, cells were washed with 1 × PBS, and cells with nuclear chromatin condensation were observed and recorded with Olympus Live Cell Fluorescence Imaging System (IX-83ZDC) with excitation at 352 nm and 20× magnification.

Mitochondria Membrane Potential (ΔΨm)
The mitochondria membrane potential (MMP) is depolarized when a cell undergoes apoptosis. Thus, MMP is an essential parameter indicating mitochondrial function, and it can be measured using the JC-1 dye. Briefly, DAergic-like neurons were seeded in 96-black well plates and treated with HS as described above. Cells were washed with PBS and then incubated with JC-1 staining solution (10 µM) in a dark room for 10 min at 37°C and 5% CO₂. After washing with PBS, red fluorescence intensity (aggregate) was measured at Ex/Em: 535/590 nm, and green fluorescence intensity (monomer) was measured at Ex/Em: 490/530 nm. The ratio between red/green was measured by dual emission florescence microplate reader (Tecan Spark 10M, Bioexpress, Switzerland). In addition, JC-1 staining was observed by dual emission fluorescence microscopy (Olympus Live Cell Fluorescence Imaging System, IX-83ZDC).

Western Blot Assay
Cells were lysed on ice with 1 × RIPA buffer containing PMSF protease inhibitor. Cell lysates were obtained by centrifugation at 10,000 RPM for 10 min at 4°C. Protein concentrations were estimated by BCA assay. Thirty micrograms of proteins from each lysate were electrophoresed and then transferred to nitrocellulose membranes. After blocking for 60 min in TBST containing 5% non-fat dried milk, the membranes were incubated overnight at 4°C with primary antibodies against Bcl-2 (1:700), Bax (1:700), β-actin (1:1,000), TH (1:1,000), and α-synuclein (1:1,000) followed by incubation with HRP-conjugated anti-rabbit or anti-mouse IgG at room temperature for 2 h. Protein bands were observed by enhanced chemiluminescence ECL on radiographic films. Relative quantities of proteins of interest were quantified by densitometric scanning and analyzed by Image J.

Statistical Analysis
Results were represented as means ± SEM and analyzed by using GraphPad Prism 5.0 (GraphPad Software). Statistical comparisons were determined by one-way ANOVA, followed by two-tailed Student’s t-test to determine significant differences between the two groups. P-values of less than 0.05 were considered statistically significant.

RESULTS
Holothuria scabra Improved Behavioral Performances of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice
Motor impairment is typically related to dopaminergic nerve injury in PD. Thus, to examine potential neuroprotective/neurorestorative effect of HS on motor impairment, we investigated the motor coordination activity and locomotor activity of mice using grid walk test. When mice were challenged with MPTP, their foot slip number during grid walk was significantly increased in association with impairments of limb motor functions and placement deficits during locomotion. On day 0, mice injected with MPTP exhibited higher foot slip number during grid walk (31.8 ± 2.90 s), compared with the control (23.7 ± 2.04 s) (Figure 2). We examined neuroprotective and neurorestorative effects of HS on motor impairments using pretreatment and post-treatment, respectively (see section “Material and
Noonong et al. Neuroprotective and Neurorestorative Effects of *Holothuria scabra* Extract

**FIGURE 2** | The number of foot slips during grid walk on day 0 and 3 after MPTP administration is shown in histograms. Data are presented as the means ± standard error of the mean (SEM) *P* < 0.05, **P* < 0.01, and ***P* < 0.001, in comparison with the NSS-injected group. ###*P* < 0.001, in comparison with the MPTP-injected group. [Graph image]

Methods” for group designation). Interestingly, the PreIP-HS/MPTP and PreG-HS/MPTP groups showed significantly reduced foot slip number during grid walk (21.5 ± 1.41 and 21.4 ± 1.42, respectively). In addition, there was a significant reduction of motor impairment in foot slip number in L-dopa, PostIP-HS/MPTP, and PostG-HS/MPTP groups when compared with the MPTP group (Figure 2). On day 3, all experimental groups showed significant reduction of foot slip number when compared to the MPTP group (Figure 2). The results of these behavioral tests indicated that HS showed efficacy in prevention and restoration of motor function in MPTP-treated mice.

*Holothuria scabra* Could Protect and Restore Dopamine Neurons and Fibers in Substantia Nigra Pars Compacta and Striatum of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice

To further assess the neuroprotective and neurorestorative effects of HS at the cellular level, we examined the expression of tyrosine hydroxylase in the pars compacta of the substantia nigra (SNpc) and striatum (STA) of mice by immunohistochemistry and counted the numbers of positive cells and fibers that appeared reddish brown in contrast to the background (Figure 3A). At day 0 in the SNpc and STA of mice treated with MPTP, the numbers of TH-positive cells and fibers significantly decreased to 60.1 ± 4.59 and 69.4 ± 19.34% (Figures 3B,C) when compared to the untreated control (100 ± 20.6 and 100 ± 23.6%). By contrast, the PreIP-HS/MPTP group showed significant increases in both TH-positive cells in SNpc (87.6 ± 8.75%) and TH-positive fibers in STA (90.6 ± 13.22%) when compared to the MPTP group. Similarly, the PreG-HS/MPTP group also showed a significant increase in the TH-positive cells in the SNpc (88.1 ± 15.84%) and TH-positive fibers in the STA (91.2 ± 15.94%) when compared with the MPTP group (Figures 3B,C). The L-dopa group did not exhibit a significant increase in both TH-positive cell in the SNpc and TH-positive fibers in STA when compared to the MPTP group. Both PostIP-HS/MPTP and PostG-HS/MPTP did not show significant increase in positive neurons in the SNpc when compared with the MPTP group, but both groups showed a significant increase in positive fibers in the STA (Figures 3B,C). On day 3, the numbers of both TH-positive cells and TH-positive fibers increased in PostIP-HS/MPTP, PostG-HS/MPTP, and L-dopa group when compared with the MPTP group, and they reached the level slightly lower than those of the PreIP-HS/MPTP and PreG-HS/MPTP groups (Figures 3B,C). This implied that post-treatment with HS after MPTP-induced PD could partially restore DA neurons and fibers in the SNpc and STA. Taken together, similar to behavioral
improvement, it appeared that HS provided a higher degree of neuroprotection than neurorestoration for both DA neurons and fibers.

**Cytotoxicity Assay**

Cytotoxicity assay was used to assess the possible toxicity of HS on DAergic-like neurons. When DAergic-like neurons were incubated with HS at concentrations of 0.5, 1, 5, 10, and 50 μg/ml for 24 h, cell viability was significantly decreased only at high concentrations of 10 and 50 μg/ml to 67.8 ± 1.21 and 45.2 ± 5.38%, respectively. When the incubation time was extended to 48 h, similar results were obtained [Figure 4A]. This indicated that HS was not toxic to DAergic-like neurons at low concentrations ranging from 0.5 to 5 μg/ml. Therefore, these
concentrations (0.5, 1, and 5 µg/ml) of HS were used for further in vitro experiments.

**Holothuria scabra** Extract Reduced Death of the 1-Methyl-4-Phenylpyridinium-Treated Dopaminergic-Like Neurons

DAergic-like neurons were pretreated with HS extract at 0.5, 1, and 5 µg/ml for 24 and 48 h and then were exposed to 500 µM MPP⁺ for 24 h. Cell viability was determined by MTT assay as described in the section “Materials and Methods.” The results showed a significant decrease in the viability of the DAergic-like neurons following exposure to 500 µM MPP⁺ for 24 h (59 ± 5.1%). Pretreatments with HS at all doses showed a significant increase in cell viability when compared to only MPP⁺ treatment with maximal number of viable cells at a concentration of 1 µg/ml of HS and 48 h incubation (Figure 4B). This indicated the neuroprotective ability of HS against MPP⁺-induced cell death in a time-dependent manner.

---

**FIGURE 4** | (A) Viability of DAergic-like neurons after incubation with HS at concentrations of 0.5, 1, 5, 10, and 50 µg/ml for 24 and 48 h. (B) Effects of HS extracts on 1-methyl-4-phenylpyridinium (MPP⁺)-induced toxicity in DAergic-like neurons. DAergic-like neurons were pretreated with HS (0.5, 1, and 5 µg/ml) for 24 and 48 h and then exposed to 500 µM MPP⁺ for 24 h. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). Data are presented as the means ± standard error of the mean (SEM) and ***P < 0.001, in comparison with the untreated group. ##P < 0.01, and ###P < 0.001, in comparison with the MPP⁺-treated group.
Holothuria scabra Extracts Reduced Mitochondria Membrane Potential (ΔΨm) Against 1-Methyl-4-Phenylpyridinium-Induced Dopaminergic-Like Neurons

Stable mitochondrial membrane potential (MMP) provided a valuable indicator of a healthy cell. The changes in MMP is considered to be one of the important events related to apoptosis (Dhanalakshmi et al., 2015). Amelioration of mitochondrial dysfunction has been proposed as a neuroprotective effect in neurodegeneration (Zhong et al., 2018). MMP changes were determined by JC-1, a mitochondria-specific dye. In normal MMP, JC-1 aggregated and shows red fluorescence, while depolarized MMP shows green fluorescence, representing apoptotic cells (Sivandzade et al., 2019). DAergic-like neurons exposed to 500 μM MPP+ for 24 h showed significant depolarization of MMP as indicated by the lower ratio of red-to-green fluorescence when compared to the control group. Also, in Figure 5A, the merged picture revealed high green fluorescence intensity in the MPP+-treated group, representing unhealthy cells undergoing apoptosis. By contrast, pretreatment with HS at 1 μg/ml remarkably increased red fluorescence, while there was a slightly decreased green fluorescence in DAergic-like neurons (Figure 5B). These results indicated that treatments with HS could attenuate the depolarization of MMP by MPP + in DAergic-like neurons.

Holothuria scabra Extracts Attenuated 1-Methyl-4-Phenylpyridinium-Induced Apoptosis and Cleaved Caspase 3 Protein Expression

To determine whether HS protected DAergic-like neurons from MPP+-induced apoptosis, Hoechst staining and Western blot analysis were conducted to analyze the nuclear morphology and apoptotic protein expressions. The results revealed that exposure to MPP+ significantly increased the number of apoptotic cells with DNA condensation (24.6%) compared to the control group (2.1%). The number of apoptotic cells significantly decreased to 7.6% when cells were pretreated with 1 μg/ml of HS (Figures 6A,B). To clarify the role of HS in attenuating MPP+-induced apoptosis, expressions of Bax, Bcl-2, and cleaved caspase 3 were investigated by Western blot. The results demonstrated that exposure to MPP+ significantly increased the level of cleaved caspase 3 expression, while it decreased Bcl-2 expression with a slight, but non-significant, increase in the level of Bax (Figures 6C,D). Pretreatments with HS significantly caused a significant increase in Bcl-2 and a reduction in cleaved caspase 3 expression, while Bax expression was also decreased but at a level not significant from that of the MPP+-treated cells (Figures 6C,D). This finding supported the notion that HS extract attenuated MPP+-induced apoptosis by increasing the expression of anti-apoptotic protein (Bcl-2) while suppressing the expression of apoptotic proteins, especially cleaved caspase 3.

Holothuria scabra Extract Increased Tyrosine Hydroxylase and Decreased α-Synuclein Expressions

To determine the neuroprotective effect of HS against MPP+-treated cells, the expression of tyrosine hydroxylase (TH), a neuron-specific marker for DAergic neurons, was determined by Western blot. After 24 h of MPP+ treatment, the expression of TH protein in treated cells was reduced by 63.8% compared with that in untreated cells. Cells pretreated with HS showed significantly increased expression of TH protein by 29.6% compared with cells treated with MPP alone (Figures 6E,F). Furthermore, cells pretreated with HS showed significantly decreased level of α-synuclein by 65.4% compared with cells treated with MPP+ alone (Figures 6E,G). These results indicated that pretreatment with HS promoted TH synthesis while suppressing the formation of α-synuclein protein.

DISCUSSION

MPTP-induced mouse model of Parkinson’s disease has been widely used and accepted for studying molecular mechanisms correlated with behavioral changes (Dawson and Dawson, 2003; Meredith and Rademacher, 2011) and initial screening of new treatments (Perry et al., 1985; Tatton and Greenwood, 1991; Meredith and Rademacher, 2011). In this context, the C57BL/6 mouse strain that is most sensitive to MPTP has been employed to study pre- and post-treatment (Przedborski et al., 2000; Sedelis et al., 2000; Bhaduri et al., 2018). The dosage and time of MPTP regimen had been applied as a subacute MPTP mouse PD model (Serra et al., 2008; Shi et al., 2016). The results showed that MPTP administration to mice induced the impairments of limb motor function and placement during locomotion, concomitantly with a significant loss of TH-positive cells and their fibers in the SNpc and in the striatum. Interestingly, HS pretreatment via intraperitoneal and oral administrations could improve the limb placement deficit without any toxicity (Supplementary Figures S1A,B). Additionally, we too observed the corresponding significant increases in DA neurons and fibers in the SNpc and STA in the pretreatment groups (Groups IV and V). As expected, these data supported the notion that HS could protect loss of dopaminergic cells with their fibers in an MPTP-induced PD mouse model, leading to behavioral improvement.

In addition to its neuroprotective effect, we further asked whether HS could also provide neurorestoration, a condition in which damaged dopaminergic neurons that still survived could be restored to their normal state (Dawson and Dawson, 2002; Airavaara et al., 2012; Francardo et al., 2017). To this end, we found that mice receiving post-treatments with HS as well as treatment with levodopa showed significant decreases in the motor impairments on day 0 and day 3 when compared with mice treated with MPTP alone. However, the degree of improvement
FIGURE 5 | The mitochondria membrane potential (MMP) was assessed by JC-1 staining. Green JC-1 monomers indicate depolarized MMP, while red JC-1 dimer indicates normal MMP. Merged panel represents colocalization between red dimer and green monomer fluorescence. (A) JC-1 staining in untreated DAergic-like neurons, DAergic-like neurons treated with 500 µM MPP⁺, DAergic-like neurons with 1 µg/ml of HS pretreatment, followed by 500 µM MPP⁺. (B) Quantitative analysis of relative fluorescence between red and green in each group as measured by microplate reader. Data are presented as the means ± standard error of the mean (SEM) **P < 0.01, in comparison with the untreated group. ###P < 0.001, in comparison with the MPP⁺-treated group.

was slightly less than the pretreated mice. L-dopa, known as a dopamine replacement, is most effective in PD. This drug can improve the motor disturbances associated with a loss of nigral dopaminergic neurons. Additionally, the restored TH-positive neurons and their fibers in L-dopa group and both post-treatment of HS performed by immunohistochemical detection were positively presented on day 3, but not on day 0. In this regard, Jin Young Shin and Hyun-Jung Park et al. demonstrated that L-dopa could rescue DA neuron death through the induction of cell survival and the suppression of apoptotic signaling in MPTP-treated PD mice via ERK activation (Shin et al., 2009). Furthermore, increased survival of dopaminergic neurons by L-dopa was dramatically observed by immunohistochemical detection. Therefore, L-dopa should be a positive control in this experiment. Similar with our neurorestoration
FIGURE 6 | (A) Effects of HS on MPP\(^+\)-induced DAergic-like neuron apoptosis shown by Hoechst 33258 stain; upper panel indicates DNA condensation in the nucleus. (B) Histograms showed percentage of apoptotic cells. (C) Expression levels of Bax, Bcl-2, and cleaved caspase 3 protein as determined by Western blot.

(Continued)
investigation, the extract from *Holothuria scabra* enriched with triterpene glycosides and polyphenol contents could restore DA neuron after 6-OHDA treatment in *Caenorhabditis elegans* model of PD (Chalorak et al., 2018). Taken together, HS exerted both neuroprotective and neurorestorative effects against deficits caused by MPTP-induced PD in mouse model, and that HS has more neuroprotective than neurorestorative efficacy.

With the neuroprotective effectiveness of HS in the mice model, we performed further investigations using MPP⁺-induced DAergic-like neurons as a cellular model of PD to understand the underlying mechanisms of neuroprotection of HS. Herein, SH-SY5Y cells were differentiated by sequential treatments with RA and TPA to become mature DAergic-like neurons as performed in many studies (Xie et al., 2010; Xicoy et al., 2017). To ensure that HS did not have any undesirable cytotoxicity on DAergic-like neurons, we performed MTT assay (Xicoy et al., 2017) and found that HS was not cytotoxic to DAergic-like neurons at concentrations below 5 µg/ml. Likewise, a previous investigation of bioactive saponin in astragaloiside IV up to 50 µM did not exert any significant toxicity in SH-SY5Y cells as measured by the MTT assay (Zhang et al., 2012). Resveratrol (5 µM), a natural polyphenolic compound, slightly promotes SH-SY5Y cell proliferation (Lee et al., 2007). Experimental evidences indicated that many natural products derived from plants, including flavonoids, steroid lactones, alkaloids, saponins, etc., exhibited a neuroprotective potential against Parkinson's disease (Subash et al., 2014). Meanwhile, the main bioactive compounds in HS comprise terpene, flavonoid, polyphenol, and alkaloid groups (Sara Bordbar et al., 2011), which might not be overly toxic to SY5Y cells. Also, these chemicals have multifunctional properties, especially in anti-oxidation property. Consequently, we conducted a pretreatment experiment and found that HS could prevent DAergic-like neuron death from MPP⁺ exposure with maximum protection at 1 µg/ml. These findings are similar to recent reports involving neuroprotection activities of bioactive compounds of plant and marine products. For instance, pretreatment with curcumin at 1 µM could protect SH-SY5Y cells from MPP⁺-induced cell death (Yu et al., 2010). Pretreatment with 20 µM of resveratrol could also protect SH-SY5Y cells from rotenone-induced neurotoxicity (Lin et al., 2014). Recently, it has been suggested that exposure to MPP⁺ resulted in the death of the DAergic-like neuron due to inhibition of the complex I in mitochondrial electron transport chain, and subsequent increase in ROS generation, leading to mitochondria membrane disruption and ATP reduction (Keane et al., 2011). Furthermore, the depolarized mitochondria membrane and the permeabilization of the outer membrane can facilitate the release of cytochrome C to promote the apoptosis pathway, causing DNA damage and cell death (Jackson-Lewis and Smeayne, 2005; Keane et al., 2011). In fact, PD is a multifactorial disease caused by oxidative stress and mitochondrial dysfunctions. Drugs that could attenuate mitochondrial impairment and render neuroprotection have gained considerable interest in PD treatment (Thomas and Beal, 2010; Jin et al., 2014; Luo et al., 2015). In our findings, pretreatment of these DAergic-like neurons with 1 µg/ml of HS could decrease mitochondria depolarization, thus resulting in the reduced expression of proapoptosis protein (BAX) and cleaved Caspase 3 expressions and the increased expression of anti-apoptosis protein (Bcl-2) when compared with MPP⁺ alone. This intriguing link seems mediated by the neuroprotective effect of HS on the MPP⁺-induced mitochondria dysfunction leading to apoptosis. Beside its negative effect on mitochondria dysfunction, several *in vitro* studies showed that MPP⁺ can induce α-synuclein expression and aggregation (Cai et al., 2009), which resulted from the impairment of the ubiquitin–proteasome system (UPS) and autophagy–lysosome pathway (ALP) (Ganguly et al., 2018). It has been proposed that α-synuclein plays an important role in initiated neurodegeneration in PD because it can interact with active biomolecules causing mitochondrial impairment, endoplasmic reticulum stress, and synaptic dysfunction (Longhena et al., 2017; Ghiglieri et al., 2018). Agents that can stabilize, degrade, clear, or inhibit the aggregated α-synuclein have been proposed as therapeutic drugs for PD (Javed et al., 2019). Here, we found that α-synuclein was upregulated in DAergic-like neurons after MPP⁺ exposure, while pretreatment with HS significantly downregulated α-synuclein accumulation. Hence, the results from our cellular model of PD demonstrated that HS provided neuroprotection for DAergic-like neurons against damage and death induced by MPP⁺ through its stimulation of anti-apoptosis proteins, improvement of mitochondrial membrane potential, increase in TH synthesis, and suppression of α-synuclein synthesis.

In conclusion, we found that HS first exerted both neuroprotective and neurorestorative effects against MPTP-induced impairments in mouse model of PD, with higher efficacy in neuroprotection than neurorestoration for both DA neurons and fibers and behavioral improvement. Neuroprotective effect of HS might be due to its stimulatory actions on the upregulation of Bcl-2 and downregulation of cleaved caspase 3 protein expressions and improved mitochondria function by preventing mitochondrial membrane depolarization. Moreover, HS could stimulate the production of tyrosine hydroxylase (TH) and decreased the production of α-synuclein. Therefore, HS could be
considered an attractive preventive and therapeutic agent for PD whose application in human PD needs further studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Care and Use Committee, Faculty of Science, Mahidol University (Approval number, MUSC58-017-332).

AUTHOR CONTRIBUTIONS

KN and KC designed the concept and coordinated this study. KN performed the experiments, analyzed, interpreted the data, and drafted the manuscript. MS supported the experiment of the animal PD mouse model. KC and PS performed critical revisions of the manuscript. All authors read and approved the final manuscript.

REFERENCES

Airavaara, M., Voutilainen, M. H., Wang, Y., and Hoffer, B. (2012). Neurorestoration. Parkinsonism Relat. Disord. 18(Suppl. 1), S143–S146. doi: 10.1016/S1353-8020(11)70045-1

Bhaduri, B., Abhilash, P. L., and Alladi, P. A. (2018). Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility. J. Chem. Neuroanat. 91, 46–54. doi: 10.1016/j.jchemneu.2018.04.005

Bordbar, S., Anwar, F., and Saarí, N. (2011). High-value components and bioactive from sea cucumbers for functional foods—A review. Mar. Drugs 9, 1761–1805. doi: 10.3390/md9101761

Cai, Z.-L., Shi, J.-J., Yang, Y.-P., Cao, B.-Y., Wang, F., Huang, J.-Z., et al. (2009). MPP+ impairs autophagic clearance of α-synuclein by impairing the activity of dyein. Neureport 20, 569–573. doi: 10.1097/WNR.0b013e328329864c

Chalorak, P., Jattujan, P., Nobsathian, S., Poomtong, T., Sobhon, P., and Meemon, K. (2018). Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: a model for anti-Parkinson testing. Nutr. Neurosci. 21, 427–438. doi: 10.1080/1028415X.2017.1299437

Dawson, T. M., and Dawson, V. L. (2002). Neuroprotective and neurorestorative strategies for Parkinson’s disease. Nat. Neurosci. 5, 1088–1091. doi: 10.1038/nn941

Dawson, T. M., and Dawson, V. L. (2003). Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302, 819–822.

Dhanalakshmi, C., Manivasagam, T., Nataraj, J., Justin Thenmozhi, A., and Essa, M. M. (2015). Neuroprotective role of vanillin, a natural phenolic compound, on rotenone induced neurotoxicity in SH-SY5Y neuroblastoma cells. Evidence Based Complementary Altern. Med. 2015:11. doi: 10.1155/2015/6266028

Francesco, V., Schmitz, Y., Sulzer, D., and Cenci, M. A. (2017). Neuroprotection and neurorestoration as experimental therapeutics for Parkinson’s disease. Exp. Neurol. 298, 137–147. doi: 10.1016/j.expneurol.2017.10.001

Ganguly, U., Chakrabarti, S. S., Kaur, U., Mukherjee, A., and Chakrabarti, S. (2018). Alpha-synuclein and Parkinson’s disease: search for neuroprotective therapy. Curr. Neuropharmacol. 16, 1086–1097. doi: 10.2174/1570159X15661712191009944

Ghiglieri, V., Calabrese, V., and Calabresi, P. (2018). α-synuclein: from early synaptic dysfunction to neurodegeneration. Front. Neurol. 9:295. doi: 10.3389/fneur.2018.00295

Honey-Escandón, M., Arreguin-Espinosa, R., Solís-Marín, F. A., and Samyn, Y. (2015). Biological and taxonomic perspective of triterpenoid glycosides of sea cucumbers of the family Holothuriidae (Echinoidea. Holothuroidea). Comp. Biochem. Physiol. Part B Biochem. Mol. Biol. 180, 16–39. doi: 10.1016/j.cbpb.2014.09.007

Jackson-Lewis, V., and Smye, R. J. (2005). “CHAPTER B3 - from man to mouse: the mptp model of parkinson disease”, in Animal Models of Movement Disorders, ed. M. LeDoux (Burlington: Academic Press), 149–160. doi: 10.1016/b978-012088382-0/50012-8

Javed, H., Nagoor Meeran, M. F., Azimullah, S., Adem, A., Sadek, B., and Ojah, S. K. (2019). Plant extracts and phytochemicals targeting α-synuclein aggregation in Parkinson’s disease models. Front. Pharmacol. 9:1555. doi: 10.3389/fphar.2018.01555

Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalayanaraman, B., and Kanthasamy, A. G. (2014). Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842, 1282–1294. doi: 10.1016/j.bbadis.2013.09.007

Keane, P. C., Kurzawa, M., Blain, P. G., and Morris, C. M. (2011). Mitochondrial dysfunction in Parkinson Disease. Parkinson’s Dis. 2011:716871. doi: 10.4061/2011/716871

Khotimchenko, Y. (2018). Pharmacological potential of sea cucumbers. Int. J. Mol. Sci. 19:1342. doi: 10.3390/ijms19051342

Kuo, P.-C., Liao, Y.-R., Hung, H.-Y., Chuang, C.-W., Hwang, T.-L., Huang, S.-C., et al. (2017). Anti-inflammatory and neuroprotective constituents from the peels of Citrus grandis. Molecules 22:967. doi: 10.3390/molecules22060967

Lee, M. K., Kang, S. J., Poncz, M., Song, K.-J., and Park, K. S. (2015). Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Amp Mol. Med. 39, 376–384. doi: 10.1038/emm.2015.74

Lin, T.-K., Chen, S.-D., Chuang, Y.-C., Lin, H.-Y., Huang, C.-R., Chuang, J.-H., et al. (2014). Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y neuroblastoma cells through induction of Heme Oxygenase-1 dependent autophagy. Int. J. Mol. Sci. 15, 1625–1646. doi: 10.3390/ijms15011625

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2020.575459/full#supplementary-material

Supplementary Figure 1 | (A) H&E staining of kidney, spleen, liver, and heart on day 0 and day 14 after mice were injected with HS 10 mg/kg/day through intraperitoneal for 7 consecutive days and received HS 200 mg/kg/day through oral gavage for 7 consecutive days. (B) Changes in the body weight gain (g) of mice received HS 10 mg/kg/day through intraperitoneal for 7 consecutive days, received HS 200 mg/kg/day through oral gavage for 7 consecutive days compared with NSS group.

FUNDING

This work was supported by the Capacity Building Program for Young Researcher Development Program from National Research Council of Thailand and Thailand Agricultural Research Development Agency (CRP5605010230, 2013).
Longhena, F., Faustini, G., Missale, C., Pizzi, M., Spano, P., and Bellucci, A. (2017). The contribution of α-synuclein spreading to Parkinson’s Disease synaptopathy. *Neural Plast.* 2017:10. doi: 10.1155/2017/5012129

Luo, Y., Hoffer, A., Hoffer, B., and Qi, X. (2015). Mitochondria: a therapeutic Target for Parkinson’s Disease? *Int. J. Mol. Sci.* 16, 20704–20703. doi: 10.3390/ijms160920704

Meredith, G. E., and Rademacher, D. J. (2011). MPTP mouse models of Parkinson’s disease: an update. *J. Parkinsons Dis.* 1, 19–33. doi: 10.3233/jpd-2011-11023

Nobisathan, S., Tuchinda, P., Sobhpon, P., Tinikul, J., Poljaronen, J., Tinikul, R., et al. (2017). An antioxidant activity of the whole body of *Holothuria scabra*. *Chemi. Biol. Technol. Agric.* 4:4. doi: 10.1186/s40538-017-0087-7

Nouroz, F., Mehbboob, M., Khan, S., and Mobin, T. (2014). Global prevalence and therapeutic strategies for Parkinson’s Disease. *Pakistan J. Clin. Biomed. Res.* 2, 48–52.

Pangestuti, R., and Arifin, Z. (2017). Medicinal and health benefit effects of functional sea cucumbers. *J. Tradit. Comp. Med.* 8, 341–351. doi: 10.1016/j.jtcme.2017.06.007

Pangestuti, R., and Kim, S.-K. (2011). Biological activities and health benefit effects of natural pigments derived from marine algae. *J. Funct. Foods* 3, 255–266. doi: 10.1016/j.jff.2011.07.001

Perry, T. L., Yong, V. W., Clavier, R. M., Jones, K., Wright, J. M., Foulks, J. G., et al. (1985). Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. *Neurosci. Lett.* 60, 109–114. doi: 10.1016/0304-3940(85)90229-0

Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Vukosavic, S., et al. (2000). The parkinsonian toxin MPTP: action and mechanism. *Restor. Neurol. Neurosci.* 16, 135–142.

Sedelis, M., Hofele, K., Auburger, G. W., Morgan, S., Huston, J. P., and Schwarting, R. K. (2000). Evidence for resistance to MPTP in C57BL/6 x BALB/c F1 hybrids as compared with their progenitor strains. *Neuroreport* 11, 1093–1096. doi: 10.1097/00001756-200004070-00037

Serra, P. A., Pluchino, S., Marchetti, B., Desole, M. S., and Miele, E. (2008). The MPTP mouse model: cues on DA release and neural stem cell restorative role. *Parkinsonism Relat. Disord.* 14(Suppl. 2), S189–S193. doi: 10.1016/j.parkreldis.2008.04.029

Shi, X., Chen, Y. H., Liu, H., and Qu, H. D. (2016). Therapeutic effects of paonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson’s disease in mice. *Mol. Med. Rep.* 14, 2397–2404. doi: 10.3892/mmr.2016.5573

Shin, J. Y., Park, H.-J., Ahn, Y. H., and Lee, P. H. (2009). Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson’s disease: a direct comparison study. *J. Neurochem* 111, 1042–1050. doi: 10.1111/j.1471-4159.2009.06381.x

Silvia Mandel, I. H., Korczyn, A. D., and Morelli, M. (2009). Prediction and Targeted Prevention of Parkinson’s and Alzheimer’s Diseases. Hauppauge, NY: Nova Science Publishers, 1–47.

Sivandzade, F., Bhalerao, A., and Cucullo, L. (2019). Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe. *Bio Protoc.* 9:e3128. doi: 10.21769/BioProtoc.3128

Solayman, M., Islam, M. A., Alam, F., Khalil, M. I., Kamal, M. A., Gan, S. H., et al. (2017). Natural products combating neurodegeneration: parkinson’s disease. *Curr. Drug Metab.* 18, 50–61. doi: 10.2174/1389200217666160709204826

Subash, S., Essa, M. M., Al-Adawi, S., Memon, M. A., Manivasagam, T., Akbar, M., et al. (2014). Neuroprotective effects of berry fruits on neurodegenerative diseases. *Neural Regen. Res.* 9, 1557–1566. doi: 10.4103/1673-5374.139483

Sun, A., Xu, X., Lin, J., Cui, X., and Xu, R. (2015). Neuroprotection by saponins. *Phytother. Res.* 29, 187–200. doi: 10.1002/ptr.5246

Tatton, W. G., and Greenwood, C. E. (1991). Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. *J. Neurosci.* 30, 666–672. doi: 10.1002/jnr.490300410

Thomas, B., and Beal, M. F. (2010). Mitochondrial therapies for Parkinson’s disease. *Mov. Disord.* 25(Suppl. 1), S155–S160. doi: 10.1002/mds.22781

Xicoy, H., Wieringa, B., and Martens, G. J. M. (2017). The SH-SYSY cell line in Parkinson’s disease research: a systematic review. *Mol. Neurodegen.* 12:10. doi: 10.1186/s13024-017-0149-0

Xie, H.-R., Li, G.-Y., and Hu, L.-S. (2010). SH-SYSY human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. *Chin. Med. J.* 123, 1086–1092. doi: 10.3760/cma.j.issn.0366-6999.2010.08.021

Yu, S., Zheng, W., Xin, N., Chi, Z.-H., Wang, N.-Q., Nie, Y.-X., et al. (2010). Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-Terminal Kinase pathway. *Rejuvenation Res.* 13, 55–64. doi: 10.1089/rrj.2009.0908

Zhang, Z.-G., Wu, L., Wang, J.-L., Yang, J.-D., Zhang, J., Zhang, J., et al. (2012). Astrapagaloside IV prevents MPP+-induced SH-SYSY cell death via the inhibition of Bax-mediated pathways and ROS production. *Mol. Cell. Biochem.* 364, 209–216. doi: 10.1007/s11010-011-1219-1

Zhong, J., Yu, H., Huang, C., Zhong, Q., Chen, Y., Xie, J., et al. (2018). Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress. *Redox Biol.* 16, 47–58. doi: 10.1016/j.redox.2018.02.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Noonong, Sobhon, Sroyraya and Chaithirayanon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.